Sandbox Reserved 1722: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 79: Line 79:
[[Image:Zinc_and_drugs_snip.PNG|450px|right|thumb|'''Figure 6''': Structures of (R)-Zinc-3573, Dextromethorphan, Morphine, and Codeine. The blue circles indicate conserved basic N-dimethyl group and the green squares show the conserved benzene rings.<ref name="Cao"/>]]
[[Image:Zinc_and_drugs_snip.PNG|450px|right|thumb|'''Figure 6''': Structures of (R)-Zinc-3573, Dextromethorphan, Morphine, and Codeine. The blue circles indicate conserved basic N-dimethyl group and the green squares show the conserved benzene rings.<ref name="Cao"/>]]


MRGPRX2 activation is associated with chronic itching or anaphylaxis reactions, a common side effect of many prescribed medications. <ref name="Cao"/> Among these drugs are opioids [https://en.wikipedia.org/wiki/Morphine morphine] and [https://en.wikipedia.org/wiki/Codeine codeine] and [https://en.wikipedia.org/wiki/Dextromethorphan dextromethorphan]. By analyzing the structures of these drugs, it can be seen that they contain chemical features similar to <scene name='90/904328/Zizwithaa/5'>agonist R-Zinc-3573</scene> (see Figure 6). They contain a conserved benzene ring that stabilizes them in binding pocket one (see Figure 6). Similarly, they contain an N-dimethyl group that would allow them to form key ionic bonds with residues Asp-184 and Glu-164. Lastly, these drugs have a similar shape and size to that of the agonist R-Zinc-3573 <ref name="Babina"> Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017</ref>. These structural and chemical similarities indicate the possibility of a similar binding mechanism to previously discussed agonist, (R)-Zinc-3573.  
MRGPRX2 activation is associated with chronic itching or anaphylaxis reactions, a common side effect of many prescribed medications <ref name="Cao"/>. Among these drugs are opioids [https://en.wikipedia.org/wiki/Morphine morphine] and [https://en.wikipedia.org/wiki/Codeine codeine] and [https://en.wikipedia.org/wiki/Dextromethorphan dextromethorphan]. By analyzing the structures of these drugs, it can be seen that they contain chemical features similar to <scene name='90/904328/Zizwithaa/5'>agonist R-Zinc-3573</scene> (see Figure 6). They contain a conserved benzene ring that stabilizes them in binding pocket 1. Similarly, they contain an N-dimethyl group that would allow them to form key ionic bonds with residues Asp-184 and Glu-164. Lastly, these drugs have a similar shape and size to that of the agonist R-Zinc-3573 <ref name="Babina"> Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017</ref> (see Figure 6). These structural and chemical similarities indicate the possibility of a similar binding mechanism to previously discussed agonist, (R)-Zinc-3573.  


This receptor is shallow and is able to bind to a variety of drugs, creating a need for a solution to mediate the effects of MRGPRX2 activation. Currently, there is research for the development of small antagonists that will induce an anti-inflammatory effect by preventing [https://en.wikipedia.org/wiki/Immunoglobulin_E IgE-dependent] mast cell degranulation <ref name="McNeil">McNeil, B. D., et al. "MRGPRX2 and Adverse Drug Reactions." Frontier Immunology, 06 August 2021, https://www.frontiersin.org/articles/10.3389/fimmu.2021.676354/full</ref>. There are two antagonists that have been adapted from being antagonists to another Class A GPCR, [https://en.wikipedia.org/wiki/NK1_receptor_antagonist neurokinin-1 receptor (NK-1R)] <ref name="Ogasawara">Ogasawara, H., et al. "Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells." Journal of Leukocyte Biology, 12 July 2019, https://jlb.onlinelibrary.wiley.com/doi/10.1002/JLB.2AB1018-405R</ref>. Through the development of this research, these adverse side effects can be relieved and improve patient satisfaction.
This receptor is shallow and is able to bind to a variety of drugs, creating a need for a solution to mediate the effects of MRGPRX2 activation. Currently, there is research for the development of small antagonists that will induce an anti-inflammatory effect by preventing [https://en.wikipedia.org/wiki/Immunoglobulin_E IgE-dependent] mast cell degranulation <ref name="McNeil">McNeil, B. D., et al. "MRGPRX2 and Adverse Drug Reactions." Frontier Immunology, 06 August 2021, https://www.frontiersin.org/articles/10.3389/fimmu.2021.676354/full</ref>. There are two antagonists that have been adapted from being antagonists to another Class A GPCR, [https://en.wikipedia.org/wiki/NK1_receptor_antagonist neurokinin-1 receptor (NK-1R)] <ref name="Ogasawara">Ogasawara, H., et al. "Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells." Journal of Leukocyte Biology, 12 July 2019, https://jlb.onlinelibrary.wiley.com/doi/10.1002/JLB.2AB1018-405R</ref>. Through the development of this research, these adverse side effects can be relieved and improve patient satisfaction.

Revision as of 15:24, 21 April 2022

This Sandbox is Reserved from February 28 through September 1, 2022 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1700 through Sandbox Reserved 1729.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Human Itch Mas-Related G-Protein Coupled Receptor

Structure of MRGPRX2 with transmembrane helices shown in blue. The domains Gαq, Gβ1, and Gγ2 are shown in purple, yellow, and pink, respectively. (PDB entry 7S8L)

Drag the structure with the mouse to rotate

References